<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020744</url>
  </required_header>
  <id_info>
    <org_study_id>1163</org_study_id>
    <nct_id>NCT04020744</nct_id>
  </id_info>
  <brief_title>Real-time fMRI Neurofeedback in Patients With MCI</brief_title>
  <official_title>Targeting Hippocampal Hyperactivity With Real-time Functional MRI Based Neurofeedback in Elderly Individuals With and Without Memory Problems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased activity in the hippocampus (i.e., hyperactivity) during a fMRI memory task was&#xD;
      found in patients with Mild Cognitive Impairment due to Alzheimer's disease (MCI). Those with&#xD;
      increased hippocampal activity exhibited elevated clinical progression. Reducing hippocampal&#xD;
      hyperactivity with pharmacological treatment reduced hyperactivity and improved memory&#xD;
      performance. The investigators of this study will test whether real-time fMRI neurofeedback&#xD;
      will also downregulate hippocampal activity and thereby improve memory performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is an insidious and progressive neurodegenerative disorder&#xD;
      accompanied by extracellular deposits of beta-amyloid ( aβ) and the increase of cognitive&#xD;
      dysfunctions. Several functional magnet resonance imaging (fMRI) studies in the prodromal&#xD;
      stage of AD (i.e., in MCI) have found increased hippocampal activity during a memory task to&#xD;
      be predictive of memory worsening and disease progression. In this study the investigators&#xD;
      are aiming to reduce hippocampal hyperactivity with real-time fMRI neurofeedback and test&#xD;
      whether this will improve memory performance.&#xD;
&#xD;
      This study will use a randomized, single-blind, parallel group design. Patients with MCI and&#xD;
      healthy participants will be assigned to receive feedback from either the hippocampus&#xD;
      (experimental group, N=42) or from another brain area (alternate ROI feedback group, N=42).&#xD;
      All participants will be instructed to downregulate activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>For blinding of the participants, they will be told that they will be asked to regulate one of two brain regions, without mentioning the specific area.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in hippocampal activity during a memory task</measure>
    <time_frame>Directly after the intervention</time_frame>
    <description>Measured by fMRI (rate of change in activity from baseline to after the intervention)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in memory performance</measure>
    <time_frame>Directly after the intervention</time_frame>
    <description>Measured by fMRI (memory performance change from baseline to after the intervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from in memory performance (behavioural)</measure>
    <time_frame>Directly after the intervention</time_frame>
    <description>Measured behaviourally (memory performance change from baseline to after the intervention)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Strategies for Regulation of hippocampal activity</measure>
    <time_frame>Intervention</time_frame>
    <description>Which strategies were particularly helpful in downregulation of hippocampal activity (number of times the strategies were mentioned)</description>
  </other_outcome>
  <other_outcome>
    <measure>Predictors of neurofeedback success</measure>
    <time_frame>Post-Intervention</time_frame>
    <description>Variables extracted from questionnaires that may predict who will respond to neurofeedback</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>healthy elderly participants receiving feedback from the hippocampus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy elderly participants receiving feedback from another area</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with MCI receiving feedback from the hippocampus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with MCI receiving feedback from another brain area</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>real-time fMRI based neurofeedback from the hippocampus</intervention_name>
    <description>During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.</description>
    <arm_group_label>healthy elderly participants receiving feedback from the hippocampus</arm_group_label>
    <arm_group_label>patients with MCI receiving feedback from the hippocampus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>real-time fMRI based neurofeedback from another brain area</intervention_name>
    <description>During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.</description>
    <arm_group_label>healthy elderly participants receiving feedback from another area</arm_group_label>
    <arm_group_label>patients with MCI receiving feedback from another brain area</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intact activities of daily living&#xD;
&#xD;
          -  Fluent in German&#xD;
&#xD;
          -  Normal/corrected-to-normal vision&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Current/lifetime severe psychiatric or neurological disorder&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Psychotropic medication&#xD;
&#xD;
          -  Currently/lifetime drug or alcohol abuse&#xD;
&#xD;
          -  Brain damage&#xD;
&#xD;
          -  Magnetisable implants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Peter, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Klöppel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Scharnowski, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Wiest, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katharina Klink</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Peter, PD Dr.</last_name>
    <phone>+41 31 932 89 03</phone>
    <email>jessica.peter@upd.unibe.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Peter</last_name>
    <phone>+41 31 932 89 03</phone>
    <email>jessica.peter@upd.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SITEM (Swiss Institute for Translational and Entrepreneurial Medicine)</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Peter, PD Dr.</last_name>
      <phone>+41319328903</phone>
      <phone_ext>+41319328903</phone_ext>
      <email>jessica.peter@upd.unibe.ch</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Klink</last_name>
      <phone>+41319328827</phone>
      <email>katharina.klink@upd.unibe.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8092</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Michels, Dr.</last_name>
      <phone>+41 44 255 49 65</phone>
      <email>lars.michels@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

